Pentacarinat

Warnings and Precautions for Pentacarinat

Pentacarinat does not use the FDA-style formal boxed warning format, as it is marketed under the UK/EU regulatory framework. However, patients and prescribers should be aware of the following important safety information from the UK Summary of Product Characteristics.

Nephrotoxicity

Nephrotoxicity is the most commonly reported adverse effect of pentamidine, usually mild and reversible. Kidney function should be monitored during treatment.

Hypotension

Hypotension can occur during or shortly after intravenous or intramuscular administration. Patients should be monitored during and after dosing, and the medicine should be administered with the patient lying down where possible.

Blood Glucose Abnormalities

Both hypoglycemia and hyperglycemia, including new-onset diabetes, have been reported with pentamidine use. Blood glucose should be monitored during and after treatment.

Handling Precautions

Pentacarinat must be reconstituted using appropriate cytotoxic-handling precautions, including preparation in a fume cupboard or equivalent controlled environment.

How to Access Pentacarinat in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation and Availability of Pentacarinat

Pentacarinat is manufactured and marketed by Sanofi under UK and EU regulatory authorization. It is sourced through authorized European distribution channels for patients seeking named-patient import into India.

Required Documentation

Patients typically need a valid prescription from a treating infectious disease specialist or physician confirming diagnosis (PCP, leishmaniasis, or trypanosomiasis) or prophylaxis indication. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.

Availability

As a UK/EU-approved therapy for these infections, Pentacarinat is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.

Sourcing and Delivery of Pentacarinat

NPP sources Pentacarinat directly from authorized European pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.

Storage and Handling

The dry powder should be stored below 30°C; once reconstituted, the solution must be stored at 2°C to 8°C and used within 24 hours. NPP maintains appropriate handling throughout transit to preserve product integrity.

Delivery Timelines

Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.

Availability of Pentacarinat Across Major Cities in India

Patients across India can access Pentacarinat through NPP's regulated import pathway, with infectious disease specialists in major cities supporting the treatment process.

Mumbai

Leading hospitals in Mumbai support infectious disease care coordination and documentation for Pentacarinat access.

Delhi

Delhi's major hospitals assist patients with prescription support and documentation for Pentacarinat.

Bangalore

Bangalore's specialist network offers access coordination for eligible patients seeking Pentacarinat.

Chennai

Chennai-based infectious disease specialists coordinate Pentacarinat access alongside comprehensive patient care.

Hyderabad

Hyderabad's care institutions support patients pursuing Pentacarinat therapy.

Kolkata

Kolkata's specialist centers help coordinate documentation and treatment access for Pentacarinat.

Pune

Pune-based specialists assist with prescription support and Pentacarinat treatment planning.

Ahmedabad

Ahmedabad's specialty hospitals support the import and treatment process for Pentacarinat.

Kochi

Kochi's specialist units assist patients with the documentation needed for Pentacarinat access.

Chandigarh

Chandigarh's care centers support Pentacarinat treatment coordination for patients from North India.

Jaipur

Jaipur's specialists help patients navigate the Pentacarinat access process.

Lucknow

Lucknow-based centers assist patients pursuing Pentacarinat therapy.

Bhubaneswar

Bhubaneswar's institutions support access to Pentacarinat for eligible patients.

Guwahati

Guwahati's specialists help coordinate Pentacarinat access for patients across the Northeast.

Patients in other cities across India can also access Pentacarinat through NPP's nationwide coordination network.